42
Participants
Start Date
November 14, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2028
TQB2102 for injection
TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Ruijin Hospital ,Shanghai Jiao Tong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Anhui Provincial Public Health Clinical Center, Hefei
NOT_YET_RECRUITING
Suzhou Municipal Hospital, Suzhou
NOT_YET_RECRUITING
Bozhou People's Hospital, Bozhou
NOT_YET_RECRUITING
Chuzhou First People's Hospital, Chuzhou
NOT_YET_RECRUITING
Wuhu Hospital Affiliated to East China Normal University, Wuhu
NOT_YET_RECRUITING
Ma'anshan People's Hospital, Ma’anshan
NOT_YET_RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
NOT_YET_RECRUITING
Wenzhou Medical University Affiliated First Hospital, Wenzhou
NOT_YET_RECRUITING
The First People's Hospital of Changde City, Changde
NOT_YET_RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
The Third People's Hospital of Zhengzhou, Zhengzhou
RECRUITING
The First People's Hospital of Zhengzhou, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
NOT_YET_RECRUITING
Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY